Cargando…
Inclusion body myositis associated with Sjögren’s syndrome
Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies. It is a poorly understood disease, which affects skeletal muscles. IBM usually occurs as an isolated condition, but in some cases, it may be associated with another autoimmune disorder, Sjögren’s syndrome. We r...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832753/ https://www.ncbi.nlm.nih.gov/pubmed/23233115 http://dx.doi.org/10.1007/s00296-012-2556-4 |
_version_ | 1782291729841389568 |
---|---|
author | Misterska-Skóra, Maria Sebastian, Agata Dzięgiel, Piotr Sebastian, Maciej Wiland, Piotr |
author_facet | Misterska-Skóra, Maria Sebastian, Agata Dzięgiel, Piotr Sebastian, Maciej Wiland, Piotr |
author_sort | Misterska-Skóra, Maria |
collection | PubMed |
description | Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies. It is a poorly understood disease, which affects skeletal muscles. IBM usually occurs as an isolated condition, but in some cases, it may be associated with another autoimmune disorder, Sjögren’s syndrome. We report a case of a 47-year-old woman with headaches, symptoms of trigeminal neuralgia, progressive weakness in muscles of the upper and lower extremities and symptoms of dry eyes and mouth. On admission, creatine kinase level was increased to 6,956 IU/mL and lactate dehydrogenase (LDH) to 1,011 U/L in the serum. The increase in inflammatory factor (CRP, ESR) levels was not found. The diagnosis of inclusion body myositis associated with Sjögren’s syndrome was established on the basis of clinical picture and diagnostic tests. In this therapy, methotrexate and methylprednisolone were administered. The considerable improved muscle strength in the upper and lower extremities, improved speech and swallowing, disappearance of headache and reduction in CPK and LDH levels were found 8 months after establishing the diagnosis. Treatment with methotrexate and methylprednisolone improved the clinical symptoms and quality of life of this patient and may offer a therapeutic option for some patients with IBM and concomitant Sjögren’s syndrome. |
format | Online Article Text |
id | pubmed-3832753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-38327532013-11-29 Inclusion body myositis associated with Sjögren’s syndrome Misterska-Skóra, Maria Sebastian, Agata Dzięgiel, Piotr Sebastian, Maciej Wiland, Piotr Rheumatol Int Short Communication Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies. It is a poorly understood disease, which affects skeletal muscles. IBM usually occurs as an isolated condition, but in some cases, it may be associated with another autoimmune disorder, Sjögren’s syndrome. We report a case of a 47-year-old woman with headaches, symptoms of trigeminal neuralgia, progressive weakness in muscles of the upper and lower extremities and symptoms of dry eyes and mouth. On admission, creatine kinase level was increased to 6,956 IU/mL and lactate dehydrogenase (LDH) to 1,011 U/L in the serum. The increase in inflammatory factor (CRP, ESR) levels was not found. The diagnosis of inclusion body myositis associated with Sjögren’s syndrome was established on the basis of clinical picture and diagnostic tests. In this therapy, methotrexate and methylprednisolone were administered. The considerable improved muscle strength in the upper and lower extremities, improved speech and swallowing, disappearance of headache and reduction in CPK and LDH levels were found 8 months after establishing the diagnosis. Treatment with methotrexate and methylprednisolone improved the clinical symptoms and quality of life of this patient and may offer a therapeutic option for some patients with IBM and concomitant Sjögren’s syndrome. Springer Berlin Heidelberg 2012-12-12 2013 /pmc/articles/PMC3832753/ /pubmed/23233115 http://dx.doi.org/10.1007/s00296-012-2556-4 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Short Communication Misterska-Skóra, Maria Sebastian, Agata Dzięgiel, Piotr Sebastian, Maciej Wiland, Piotr Inclusion body myositis associated with Sjögren’s syndrome |
title | Inclusion body myositis associated with Sjögren’s syndrome |
title_full | Inclusion body myositis associated with Sjögren’s syndrome |
title_fullStr | Inclusion body myositis associated with Sjögren’s syndrome |
title_full_unstemmed | Inclusion body myositis associated with Sjögren’s syndrome |
title_short | Inclusion body myositis associated with Sjögren’s syndrome |
title_sort | inclusion body myositis associated with sjögren’s syndrome |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832753/ https://www.ncbi.nlm.nih.gov/pubmed/23233115 http://dx.doi.org/10.1007/s00296-012-2556-4 |
work_keys_str_mv | AT misterskaskoramaria inclusionbodymyositisassociatedwithsjogrenssyndrome AT sebastianagata inclusionbodymyositisassociatedwithsjogrenssyndrome AT dziegielpiotr inclusionbodymyositisassociatedwithsjogrenssyndrome AT sebastianmaciej inclusionbodymyositisassociatedwithsjogrenssyndrome AT wilandpiotr inclusionbodymyositisassociatedwithsjogrenssyndrome |